Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.

Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer. Clin Adv Hematol Oncol. 2019 Mar;17 Suppl 7(3):5-13 Authors: Bekaii-Saab T PMID: 31730590 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Related Links:

Condition:   Colorectal Cancer Interventions:   Dietary Supplement: Magnesium glycinate;   Dietary Supplement: Placebo Sponsor:   Vanderbilt University Medical Center Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Colo-rectal Cancer;   Polyp of Colon;   Adenomatous Polyps Intervention:   Device: EndoVigilant CAD Software Sponsor:   EndoVigilant Inc Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Liu T, Li C, Jin L, Li C, Wang L Abstract BACKGROUND The RNA-seq FPKM data of 331 colorectal adenocarcinoma samples in The Cancer Genome Atlas database with matching clinical data were analyzed in order to reveal the prognostic value of m6A RNA methylation regulators in colon adenocarcinoma. MATERIAL AND METHODS The expression of 13 m6A RNA methylated regulators in samples were analyzed. The samples were classified into Cluster I and II by consistent clustering. The gene distribution was analyzed by principal component analysis. Further functional analysis of selected m6A RNA genes was performed and potent...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
I first became John Dolan ’s social worker following his colon surgery, surgery for removal of a very large cancerous tumor, the largest the experienced surgeon said he had ever seen.  John was told he had about three months to live. So much for predictions!  He lived another 16 months. To the chagrin of his very […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Oncology/Hematology Source Type: blogs
Publication date: February 2020Source: Cancer Epidemiology, Volume 64Author(s): Alexandra Blair, Geetanjali D. DattaAbstractBackgroundImportant social disparities in colorectal screening exist in Canada. Few studies have assessed disparities further along the cancer control continuum. Here we assess the associations between social and material deprivation, physician density, rural residence, and the absence of provincial mail-based screening programs and colorectal cancer (CRC) stage at diagnosis.MethodsColorectal cancer cases and stage data (“local or regional” if stage 0, I, or II, “late” if stage...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Authors: Zhou JM, Jiang H, Yuan T, Zhou GX, Li XB, Wen KM Abstract Heterogeneous ribonucleoprotein AB (hnRNP AB) is a member of the heterogeneous nuclear ribonucleoprotein family, which serves important functions in gene expression and signal transduction. However, the expression and clinicopathological significance of hnRNP AB in colorectal cancer (CRC) remain to be elucidated. To investigate the expression and clinical significance of hnRNP AB in CRC, hnRNP AB expression levels were analysed in two independent cohorts of patients with CRC. The results of reverse transcription-quantitative PCR, immunohistochemistr...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Batra A, Cheung WY Abstract The term "real-world evidence" (rwe) describes the analysis of data that are collected beyond the context of clinical trials. The use and application of rwe have become increasingly common and relevant, especially in oncology, because there is growing recognition that randomized controlled trials (rcts) might not be sufficiently representative of the entire patient population that is affected by cancer, and that specific clinical research questions might be best addressed by real-world data. In this brief review, our main aim is to highlight the role of rwe in informin...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of thera...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Authors: Jin Z, Hubbard JM Abstract Significant advances in the treatment of metastatic colorectal cancer (mcrc) since the early 2000s have led to improved clinical outcomes, including overall survival (os). When fluorouracil was the sole treatment agent for mcrc, os in phase iii studies was approximately 12 months. Now, in 2019, the median os (mos) in the most recent mcrc clinical trials has been approaching 3 years. The biologic agents that target the vascular endothelial growth factor (vegf), epithelial growth factor receptor (egfr), human epidermal growth factor receptor 2 (her2), PD-1, ctla-4, ntrk, and braf p...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Authors: Parmar A, Chan KKW, Ko YJ Abstract Therapeutic options for chemorefractory metastatic colorectal cancer (mcrc) have significantly expanded since 2009. The oral targeted therapies regorafenib and trifluridine/tipiracil have been established to be efficacious and safe in patients with mcrc who have progressed beyond 2 or more lines of chemotherapy. Evidence for the use of immunotherapy in a subgroup of this patient population is also encouraging, particularly in patients with mcrc that exhibits high microsatellite instability or deficient mismatch repair. Those significant advances have led to Health Canada ...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Hematology